International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

被引:329
作者
Dawood, S. [2 ]
Merajver, S. D. [3 ]
Viens, P. [4 ]
Vermeulen, P. B. [5 ]
Swain, S. M. [6 ]
Buchholz, T. A. [7 ]
Dirix, L. Y. [8 ]
Levine, P. H. [9 ]
Lucci, A. [10 ]
Krishnamurthy, S. [11 ]
Robertson, F. M. [12 ]
Woodward, W. A. [7 ]
Yang, W. T. [13 ]
Ueno, N. T. [14 ]
Cristofanilli, M. [1 ]
机构
[1] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[2] Dubai Hosp, Dept Hlth & Med Serv, Dept Med Oncol, Dubai, U Arab Emirates
[3] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[4] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France
[5] Gen Hosp Sint Augustinus, Dept Pathol, Antwerp, Belgium
[6] Washington Hosp Ctr, Washington Canc Inst, Washington, DC 20010 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[8] Gen Hosp Sint Augustinus, Translat Canc Res Grp Antwerp, Antwerp, Belgium
[9] George Washington Univ, Dept Epidemiol & Biostat, Sch Publ Hlth & Hlth Serv, Washington, DC USA
[10] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[12] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[13] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA
[14] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
关键词
guidelines; inflammatory breast cancer; management; POSITRON-EMISSION-TOMOGRAPHY; STEM-CELL TRANSPLANTATION; GROWTH-FACTOR; RHOC-GTPASE; NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL DEFINITION; TREATMENT OUTCOMES; STAGE-III; FOLLOW-UP; PHASE-II;
D O I
10.1093/annonc/mdq345
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed with non-IBC tumors. Recommendations and guidelines published to date on the diagnosis, management, and follow-up of women with breast cancer have focused primarily on non-IBC tumors. Establishing a minimum standard for clinical diagnosis and treatment of IBC is needed. Methods: Recognizing IBC to be a distinct entity, a group of international experts met in December 2008 at the First International Conference on Inflammatory Breast Cancer to develop guidelines for the management of IBC. Results: The panel of leading IBC experts formed a consensus on the minimum requirements to accurately diagnose IBC, supported by pathological confirmation. In addition, the panel emphasized a multimodality approach of systemic chemotherapy, surgery, and radiation therapy. Conclusions: The goal of these guidelines, based on an expert consensus after careful review of published data, is to help the clinical diagnosis of this rare disease and to standardize management of IBC among treating physicians in both the academic and community settings.
引用
收藏
页码:515 / 523
页数:9
相关论文
共 65 条
  • [1] Alpaugh ML, 1999, CANCER RES, V59, P5079
  • [2] [Anonymous], PLAST RECONSTR SURG
  • [3] [Anonymous], AAJCC CANC STAGING M
  • [4] Baldini Editta, 2004, Clin Breast Cancer, V5, P358, DOI 10.3816/CBC.2004.n.042
  • [5] Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC)
    Bellon, JR
    Livingston, RB
    Eubank, WB
    Gralow, JR
    Ellis, GK
    Dunnwald, LK
    Mankoff, DA
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (04): : 407 - 410
  • [6] INFLAMMATORY CARCINOMAS OF THE BREAST - A CLINICAL, PATHOLOGICAL, OR A CLINICAL AND PATHOLOGICAL DEFINITION
    BONNIER, P
    CHARPIN, C
    LEJEUNE, C
    ROMAIN, S
    TUBIANA, N
    BEEDASSY, B
    MARTIN, PM
    SERMENT, H
    PIANA, L
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (04) : 382 - 385
  • [7] Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
    Bristol, Ian J.
    Woodward, Wendy A.
    Strom, Eric A.
    Cristofanilli, Massimo
    Domain, Delora
    Singletary, S. Eva
    Perkins, George H.
    Oh, Julia L.
    Yu, Tse-Kuan
    Terrefe, Welela
    Sahin, Aysegul A.
    Hunt, Kelly K.
    Hortobagyi, Gabriel N.
    Buchholz, Thomas A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (02): : 474 - 484
  • [8] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study
    Burstein, HJ
    Harris, LN
    Gelman, R
    Lester, SC
    Nunes, RA
    Kaelin, CM
    Parker, LM
    Ellisen, LW
    Kuter, I
    Gadd, MA
    Christian, RL
    Kennedy, PR
    Borges, VF
    Bunnell, CA
    Younger, J
    Smith, BL
    Winer, EP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 46 - 53
  • [9] Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer
    Cabioglu, N.
    Gong, Y.
    Islam, R.
    Broglio, K. R.
    Sneige, N.
    Sahin, A.
    Gonzalez-Angulo, A. M.
    Morandi, P.
    Bucana, C.
    Hortobagyi, G. N.
    Cristofanilli, M.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (06) : 1021 - 1029
  • [10] Retrospective Studyof 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data
    Carkaci, Selin
    Macapinlac, Homer A.
    Cristofanilli, Massirno
    Mawlawi, Osama
    Rohren, Eric
    Angulo, Ana M. Gonzalez
    Dawood, Shaheenah
    Resetkova, Erika
    Le-Petross, Hliong T.
    Yang, Wei-Tse
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (02) : 231 - 238